Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis

• Published in: Archives of physiology and biochemistry Vol. 126; no. 2; pp. 172 - 182
• Main Authors: Fawzy, Manal S., Abu AlSel, Baraah T., Al Ageeli, Essam, Al-Qahtani, Saeed Awad, Abdel-Daim, Mohamed M., Toraih, Eman A.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 14.03.2020
• Subjects: Adult; Aged; Base Pairing; Base Sequence; Cross-Sectional Studies; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - therapy; Diabetic Nephropathies - diagnosis; Diabetic Nephropathies - etiology; Diabetic Nephropathies - genetics; Diabetic Nephropathies - therapy; Disease Progression; End-stage renal disease; Female; gene expression; Gene Expression Regulation; Humans; Kidney Failure, Chronic - diagnosis; Kidney Failure, Chronic - etiology; Kidney Failure, Chronic - genetics; Kidney Failure, Chronic - therapy; MALAT1; Male; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; miR-499a; qRT-PCR; Renal Dialysis; RNA, Long Noncoding - blood; RNA, Long Noncoding - genetics; End-stage renal disease; MALAT1; miR-499a; gene expression; qRT-PCR
• ISSN: 1381-3455; 1744-4160; 1744-4160
• DOI: 10.1080/13813455.2018.1499119

Background: Circulating non-coding RNAs (ncRNAs) have been implicated in health and disease. This study aimed to evaluate the serum expression profile of microRNA-499a (miR-499a) and its selected bioinformatically predicted partner long-ncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) in diabetes-related end-stage renal disease (ESRD) patients and to correlate the expressions with the patients' clinicolaboratory data. Subjects and methods: Real-time quantitative polymerase chain reaction was applied in diabetics with and without ESRD (n = 90 for each). Results: Serum MALAT1 expression levels were increased in the ESRD group relative to diabetics without ESRD with median (quartile) values of 10.5 (1.41-126.7) (p < .001). However, miR-499a levels were decreased in more than half of ESRD patients with a median of 0.96 (0.13-3.14). Both MALAT1 and miR-499a expression levels were inversely correlated in the ESRD patient-group. Conclusions: MALAT1 up-regulation and miR-499 down-regulation might be involved in diabetic nephropathy-related ESRD pathogenesis. Functional validation studies are warranted to confirm the MALAT1/miR-499a partnership.